Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] - 1 Jan 2000

Luo Guopei, Guo Meng, Jin Kaizhou, Liu Zuqiang, Liu Chen, Cheng He, Lu Yu, Long Jiang, Liu Liang, Xu Jin, Ni Quanxing, Yu Xianjun

Abstract excerpt

BACKGROUND: Carbohydrate antigen 19-9 (CA19-9) is currently the most widely used biomarker for pancreatic cancer. It is well-known that Lewis and Secretor status can affect CA19-9 biosynthesis. This study was performed to optimize CA19-9 in detecting pancreatic cancer using Lewis and Secretor dependent cut-off values. METHODS: Lewis and Secretor genotypes were determined by Sanger sequencing in a large cohort of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CA-19-9 Antigen

Share to Cohort Studies

Share to Neoplasm Staging

Share to Pancreatic Diseases

Share to Pancreatic Neoplasms

Share to Predictive Value of Tests

Source

Identifiers

PMID: 27692554
DOI: 10.1016/j.pan.2016.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.PMID 27692554Read ↗

New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.Semantic proximity Read ↗

Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.Semantic proximity Read ↗

A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.Semantic proximity Read ↗

Glycans Related to the CA19-9 Antigen Are Increased in Distinct Subsets of Pancreatic Cancers and Improve Diagnostic Accuracy Over CA19-9Semantic proximity Read ↗

CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.Semantic proximity Read ↗

Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic CancerSemantic proximity Read ↗

The relationship between Lewis/Secretor genotypes and serum carbohydrate antigen 19-9 levels in a Korean population.Semantic proximity Read ↗

Current State of “Omics” Biomarkers in Pancreatic CancerSemantic proximity Read ↗

Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.Semantic proximity Read ↗

Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.Semantic proximity Read ↗

Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients.Semantic proximity Read ↗

The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.